Anophthalmia and Microphthalmia Market is Expected to Grow at a CAGR over ~4.70% from 2022 to 2030

Pune, India, November, 2022/MRFR Press Release/- Market Research Future has a half cooked research report on the global anophthalmia and microphthalmia market.

Market Highlights

Anophthalmia and microphthalmia may occur during development of the eye at various stages of growth of the optic vesicle. The prevalence of this disease is considered rare. It is important to recognize microphthalmia because the development of the orbital region, as well as the lids and the fornices.

Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth during the period 2017-2023.

The Anophthalmia and Microphthalmia Market is expected to reach USD 5,967.90 Million by 2030 at 4.70% CAGR during the forecast period 2022 -2030

Regional Analysis

The Americas dominate the global anophthalmia and microphthalmia market owing to the presence of huge patient population with eye related problems, neurological disabilities, high healthcare spending, and increasing government support for research & development.  

Europe holds the second largest share of the global anophthalmia and microphthalmia market as result of increasing focus of various government agencies on the treatment of rare diseases such as acquired aplastic anemia. Moreover, the growing public awareness about anophthalmia and microphthalmia likely to boost the Europe market. According to reports from European Association for Vision and Eye Research, cases of anophthalmia and microphthalmia were identified, with a rate of 3.21 per 10,000 live births.  Of which the eye defects were isolated in 5 cases (5.2%), and 24 cases (25.0%) had confirmed chromosomal abnormalities.

Asia Pacific is the fastest growing anophthalmia and microphthalmia market across the globe. Japan holds the major share of the regional market due to availability of advanced technology and huge healthcare spending. Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in China and India over the forecasted period.

The Middle East and Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.  

Segmentation

The global anophthalmia and microphthalmia market is segmented on the basis by diagnosis, by treatment, and by end user. On the basis of diagnosis, it is segmented into CT scan, MR scan, chromosome analysis, ultrasonography, and others. On the basis of treatment, it is segmented into surgery, and others. On the basis of end user, it is segmented into hospitals & clinics, research centers, and others.

Key Players

Some of key the players in the market are Bristol-Myers Squibb Company, NUSAPURE, ALLERGAN, Aerie Pharmaceuticals, Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Bayer AG, Genentech, Inc., Novartis AG , Regeneron Pharmaceuticals, Inc., Shire, and Santen Pharmaceutical Co., Ltd., and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Anophthalmia and Microphthalmia Market Research Report